As observed in preclinical studies, the lower anti-tumor activity of high-dose NGR-hTNF (45 μg/m2) seemed to be related to the induction of soluble TNF-receptors shedding in the circulation, i.e., the release of TNF inhibitors. Here, TNF is linked to neoplasm.